Any positives?, page-240

Hey Goldie, you really have no concept of what they are trying to achieve with the Eugeni platform, do you? It is a POC diagnostic platform. Of course ADO have missed the huge wave of RAT's being bought up globally, and it would indeed have been nice to have taken some (or any) of that short term market share. However it did, with the hype of it all, secure funding to roll out Eugeni as a platform. And there is a huge future in POC diagnostics.

Covid may be currently waning. And it may indeed become endemic, with seasonal variants. But that is exactly what has happened with influenza, and whilst it may not receive the headlines Covid does, the flu does kill a lot of people each year. It costs society a lot. There are biotech/diagnostic companies out there currently making money from the diagnosis of flu (Ellume were on track prior to Covid). So why can't ADO do similar with Covid moving forward? And given that Eugeni is a platform, and ADO have repeatedly ear-marked the development of a range of further tests (Covid/flu mutiplex, sepsis, cardiac etc), surely writing off ADO's ability to commercialise based on this current waning of Covid is short sighted.

If you want to trade the volatility of this stock - that is fine. But please don't lecture long term investors on why they have invested. I invested in ADO back when they were in development with Phillips and their Minicare platform. Yep, that one failed. Then we were in the Diasource wasteland for a while. The direction we are headed in now is so exciting. Sure, mistakes have been made, timelines blown, and I was gutted at the poor progress announced in the webinar, and immediately lost a lot of respect for DT, whom I thought had been acting with so much integrity. There probably will be more mistakes as well. But this was their first shot at scale up of their first test on their first platform.

They have cash in the bank, they now have a clearer path to get regulatory approvals for the standalone Covid test. It might not bring in millions p/a, but the knowledge gained will be invaluable for the rollout of the future tests on this platform. And then there is always batteries....